Institutional members access full text with Ovid®

Share this article on:

Adenocarcinoma of the Male Breast after Spironolactone-Induced Gynecomastia: Case Report.

Wilson Rodman M.D.;; Lanier, James M.D.;
The Endocrinologist: March 1996
Editorial: PDF Only

A man was given spironolactone and other drugs intermittently for control of hypertension. He developed gynecomastia bilaterally; spironolactone was stopped. Three years later, fatal infiltrating ductal adenocarcinoma of the breast supervened. This sequence of events raises suspicion that spironolactone therapy led to lethal breast carcinoma.

(C) Lippincott-Raven Publishers.